Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Interplay between MexAB-OprM and MexEF-OprN in clinical isolates of Pseudomonas aeruginosa

dc.contributor.authorHorna, Gertrudis
dc.contributor.authorLópez, María
dc.contributor.authorGuerra, Humberto
dc.contributor.authorSáenz, Yolanda
dc.contributor.authorRuiz, Joaquim
dc.date.accessioned2019-06-05T14:11:50Z
dc.date.available2019-06-05T14:11:50Z
dc.date.issued2018-11-07
dc.date.updated2019-05-27T08:59:38Z
dc.description.abstractMexAB-OprM and MexEF-OprN are Pseudomonas aeruginosa efflux pumps involved in the development of antibiotic resistance. Several studies developed with laboratory strains or using a few clinical isolates have reported that the regulation system of MexEF-OprN is involved in the final levels of MexAB-OprM expression. Therefore, this study was aimed to determine the interplay between MexAB-OprM and MexEF-OprN in 90 out of 190 P. aeruginosa clinical isolates with an efflux pump overexpression phenotype. Regarding oprD, 33% (30/90) of isolates displayed relevant modifications (RM) defined as frameshift or premature stop, both related to carbapenem resistance. On the other hand, 33% of the isolates displayed RM in nalC, nalD or mexR, which were significantly associated with multidrug resistance (MDR), non-susceptibility to carbapenems, OprD alterations and strong biofilm production. Meanwhile, the RM in MexS were associated with presence of pigment (p = 0.004). Otherwise, when all the regulators were analysed together, the association between RM in MexAB-OprM regulators and MDR was only significant (p = 0.039) when mexS was the wild type. These data show the modulatory effect of MexEF-OprN on MexAB-OprM in a clinical population of P. aeruginosa. Further studies may contribute to design of novel molecules acting on this interplay to fight against antimicrobial resistance.
dc.format.extent11 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn2045-2322
dc.identifier.pmid30405166
dc.identifier.urihttps://hdl.handle.net/2445/134579
dc.language.isoeng
dc.publisherNature Publishing Group
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1038/s41598-018-34694-z
dc.relation.ispartofScientific Reports, 2018, vol. 8
dc.relation.urihttp://dx.doi.org/10.1038/s41598-018-34694-z
dc.rightscc by (c) Horna et al., 2018
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/
dc.sourceArticles publicats en revistes (ISGlobal)
dc.subject.classificationPseudomonas
dc.subject.classificationResistència als medicaments
dc.subject.otherDrug resistance
dc.titleInterplay between MexAB-OprM and MexEF-OprN in clinical isolates of Pseudomonas aeruginosa
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
Horna_G_Sci_Rep_2018.pdf
Mida:
1.53 MB
Format:
Adobe Portable Document Format